IP Library Granted Patent US 10,322,173
Granted Patent B2
US 10,322,173 · App. 15/111,797 · Granted Jun 18, 2019

Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent

Inventors: Takefumi Gemba (Kagoshima, JP); Ryoichi Nagata (Kagoshima, JP)
Assignees: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.; WAVE LIFE SCIENCES JAPAN, INC.
A61K39/39A61K31/7125A61K48/00C12N15/117A61K2039/55561C12N2310/17C12N2310/315C12N2310/344
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,322,173
App. No.
15/111,797
Granted
Jun 18, 2019
Kind
B2
Abstract

Problem To provide a chiral nucleic acid adjuvant and anti-allergic agent having anti-allergic effect. Solution An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5′-X 1 CpGX 2 -3′ and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3′ end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3′ end and 5′ end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.

Claims (7)

1. A method for treating an allergic reaction, comprising administering to a subject a composition comprising a therapeutically effective amount of the oligonucleotide

T SP C SP GACGTT SP T SP T SP GACGTT SP T SP T SP GACG SP T SP T,

wherein each SP represents an S type phosphorothioate linkage.

2. The method as claimed in claim 1 , further comprising administering an anti-allergic agent.

3. A method for treating an allergic rhinitis, comprising administering to a subject a composition comprising a therapeutically effective amount of the oligonucleotide

T SP C SP GACGTT SP T SP T SP GACGTT SP T SP T SP GACG SP T SP T

wherein each SP represents an S type phosphorothioate linkage.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2018
From: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
To: WAVE LIFE SCIENCES JAPAN, INC.
Reel/Frame 047303/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2017
From: GEMBA, TAKEFUMI; NAGATA, RYOICHI
To: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Reel/Frame 041371/0638 →
Priority Claims (1)
JP 2014-005508 · Jan 15, 2014 · national
Continuity (1)
Related Publication 20160331835A1 · Nov 17, 2016
Cited By (10)
US 12,391,942 US 12,403,156 US 12,428,442 US 12,435,105 US 12,473,321 US 12,486,505 US 12,552,743 US 12,590,115 US 12,637,672 US 12,674,168